Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Retatrutide is an investigational triple-action medication that targets the GIP, GLP-1, and glucagon receptors simultaneously
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide carry the clinical evidence: STEP for semaglutide ( The New England Journal of Medicine , 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024)
Prophylactic neck dissection (ie, elective neck dissection) is not advocated as a treatment for oral melanoma
Patients are encouraged to speak with their GP or a specialist weight management service to explore currently available, approved treatment options
Haibo Si, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
PBS) at 15 min compared to PBS control, where 1/2 of this total GLP-1 in the gastric vein is the active peptide (Ribeiro-Parenti et al., 2021)
US$ 26.84
US$ 28.75
US$ 20.20
